TRPC6 and focal segmental glomerulosclerosis: In summary, the discovery that gain-of-function mutations in TRPC6 caused familial forms of FSGS generated significant interest in targeting TRPC6, and perhaps other TRPC family members, to treat glomerular disease processes.